Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant chemotherapy with or without bevacizumab followed by endocrine therapy with or without capivasertib in hormone receptor-positive breast cancer
2021-005850-27Phase 2Active
- Sponsor
- Oslo University Hospital
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and capivasertib in breast cancer (4 arms), sponsored by Oslo University Hospital. Primary endpoint: Primary Outcome Measure Part 1 (Chemotherapy). Started Jan 2022; status: active.
02
Drugs
bevacizumabcapivasertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-005850-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005850-27.